Similar articles

• BIS-1: a novel bispecific monoclonal antibody for CEA-expressing carcinoma radioimmunoscintigraphy and radioimmunotherapy.

  Parisi A, Bartolazzi A, Bonino C, Camagna M, DeMonte LB, Lombardi A, Natali PG, Paganelli G, Tarditi L, Vassarotto C, et al. Parisi A, et al. Year Immunol. 1993;7:96-105. Year Immunol. 1993. PMID: 8372516 No abstract available.
• Generation of bispecific monoclonal antibodies for two phase radioimmunotherapy.

  Bosslet K, Steinstraesser A, Hermentin P, Kuhlmann L, Bruynck A, Magerstaedt M, Seemann G, Schwarz A, Sedlacek HH. Bosslet K, et al. Br J Cancer. 1991 May;63(5):681-6. doi: 10.1038/bjc.1991.155. Br J Cancer. 1991. PMID: 2039692 Free PMC article.
• Carcinoembryonic antigen as a target for radioimmunotherapy of human medullary thyroid carcinoma: antibody processing, targeting, and experimental therapy with 131I and 90Y labeled MAbs.

  Stein R, Juweid M, Mattes MJ, Goldenberg DM. Stein R, et al. Cancer Biother Radiopharm. 1999 Feb;14(1):37-47. doi: 10.1089/cbr.1999.14.37. Cancer Biother Radiopharm. 1999. PMID: 10850286
• Preparation and use of DTPA-coupled antitumor antibodies radiolabeled with yttrium-90.

  Hnatowich DJ, Snook D, Rowlinson G, Stewart S, Epenetos AA. Hnatowich DJ, et al. Targeted Diagn Ther. 1988;1:353-74. Targeted Diagn Ther. 1988. PMID: 2979062 Review. No abstract available.
• Antibody targeted therapy in cancer: comparison of murine and clinical studies.

  Begent RH, Pedley RB. Begent RH, et al. Cancer Treat Rev. 1990 Sep;17(2-3):373-8. doi: 10.1016/0305-7372(90)90071-m. Cancer Treat Rev. 1990. PMID: 2272053 Review.